AI Article Synopsis
- Metabolic dysfunction and inflammation may affect endometrial cancer risk, but their impact on survival rates is not well understood.
- A study with 540 endometrial cancer patients collected blood samples to analyze various biomarkers and assessed survival outcomes over a median of 14.3 years.
- The study found no significant associations between most biomarkers and survival, but higher presurgical levels of adiponectin were linked to better disease-free and overall survival, suggesting the need for further research.
Article Abstract
Background: Metabolic dysfunction and inflammation have been associated with endometrial cancer risk; however, their influence on endometrial cancer survival is less understood.
Methods: A prospective cohort study of 540 endometrial cancer cases diagnosed between 2002 and 2006 in Alberta were followed for survival outcomes to 2019. Baseline blood samples collected either pre- or post-hysterectomy were analyzed for glucose, insulin, adiponectin, leptin, tumor necrosis factor-α, interleukin-6, and C-reactive protein. Covariates were obtained during in-person interviews and via medical chart abstraction. Cox proportional hazard regression models were used to estimate multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (95% CI) for the association between each biomarker and disease-free and overall survival.
Results: Blood samples were collected from 520 of the 540 participants (presurgical n = 235; postsurgical n = 285). During the median follow-up of 14.3 years (range 0.4-16.5 years), there were 125 recurrences, progressions, and/or deaths with 106 overall deaths. None of the biomarkers were associated with disease-free or overall survival in multivariable-adjusted analyses. In an exploratory stratified analysis, the highest level of presurgical adiponectin, compared to the lowest level, was associated with improved disease-free (HR = 0.42, 95% CI = 0.20-0.85) and overall (HR = 0.41, 95% CI = 0.18-0.92) survival, whereas no statistically significant associations were noted for postsurgical measures of adiponectin.
Conclusions: Overall, there was no evidence of an association between biomarkers of insulin resistance and inflammation with mortality outcomes in endometrial cancer survivors. Future cohort studies with serial blood samples are needed to understand the impact of changes in insulin resistance and inflammatory markers on endometrial cancer survival.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986143 | PMC |
| http://dx.doi.org/10.1002/cam4.4584 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting undruggable protein KRAS for cancer therapy: novel opportunities and challenges.
Future Med Chem
December 2024
Henan Children's Hospital, Zhengzhou Children's Hospital, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
Incidence and risk factors of hepatitis E virus infection in women with gynecological tumors in Eastern China.
PeerJ
December 2024
Department of Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Background: Recently, there has been increasing interest in the exploration of the association between the hepatitis E virus () infection and malignancies; however, epidemiological data for infection among women with a gynecological tumors (GT) are limited. Herein, we investigated the correlation between and GT in Chinese women.
Methods: We recruited 452 women diagnosed with a primary GT and 452 healthy volunteers to investigate the possible routes and risk factors for infection.
Explainable machine learning for predicting recurrence-free survival in endometrial carcinosarcoma patients.
Front Artif Intell
December 2024
Laboratorio di Biostatistica e Bioinformatica, Fisica Sanitaria, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Objectives: Endometrial carcinosarcoma is a rare, aggressive high-grade endometrial cancer, accounting for about 5% of all uterine cancers and 15% of deaths from uterine cancers. The treatment can be complex, and the prognosis is poor. Its increasing incidence underscores the urgent requirement for personalized approaches in managing such challenging diseases.
View Article and Find Full Text PDFA potential inflammatory biomarker for advanced endometrial cancer treated with lenvatinib plus pembrolizumab.
J Obstet Gynaecol Res
January 2025
Department of Obstetrics and Gynecology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Introduction: To identify prognostic biomarkers that could predict how well patients will respond to lenvatinib/pembrolizumab (LEN/PEM). The utility of certain inflammatory biomarkers in endometrial liquid-based cytology (LBC) or peripheral blood samples, such as neutrophil counts, lymphocyte counts, and neutrophil-to-lymphocyte ratio (NLR) were explored.
Methods: The study included 25 patients with advanced or recurrent endometrial cancer who had received LEN/PEM between August 2018 and March 2024.
Deep learning for endometrial cancer subtyping and predicting tumor mutational burden from histopathological slides.
NPJ Precis Oncol
December 2024
Institute of Pathology and Parasitology, National Defense Medical Center, Taipei, Taiwan.
Endometrial cancer (EC) diagnosis traditionally relies on tumor morphology and nuclear grade, but personalized therapy demands a deeper understanding of tumor mutational burden (TMB), i.e., a key biomarker for immune checkpoint inhibition and immunotherapy response.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!